Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation

Abstract

Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K . (1997). Cell, 89, 1175–1184.

  • Bergamaschi D, Samuel Y, O’Neil NJ, Trigiante G, Crook T, Hsieh KJ, O’Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE and Lu X . (2003). Nat. Genet., 33, 162–167.

  • Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb A, Jochemsen AG and Lane DP . (1999). Oncogene, 18, 189–199.

  • Caelles C, Helmberg A and Karin M . (1994). Nature, 370, 220–223.

  • Chen J, Marechal V and Levine AJ . (1993). Mol. Cell. Biol., 13, 4107–4114.

  • Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR . (2004). Science, 303, 1010–1014.

  • Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ . (1994). Cancer Res., 54, 794–799.

  • Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG and Marine JC . (2004). Mol. Cell. Biol., 24, 5835–5843.

  • de Oca Luna RM, Wagner DS and Lozano G . (1995). Nature, 378, 203–206.

  • Haupt Y, Maya R, Kazaz A and Oren M . (1997). Nature, 387, 296–299.

  • Jackson MW and Berberich SJ . (2000). Mol. Cell. Biol., 20, 1001–1007.

  • Jones SN, Roe AE, Donehower LA and Bradley A . (1995). Nature, 378, 206–208.

  • Kubbutat MH, Jones SN and Vousden KH . (1997). Nature, 387, 299–303.

  • Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM . (1997). Nature, 387, 823–826.

  • Lin J, Chen J, Elenbaas B and Levine AJ . (1994). Genes Dev., 8, 1235–1246.

  • Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM . (2003). Mol. Cell, 11, 577–590.

  • Moll UM and Zaika A . (2001). FEBS Lett., 493, 65–69.

  • Momand J, Zambetti GP, Oslon DC, George D and Levine AJ . (1992). Cell, 69, 1237–1245.

  • Oliner JD, Pietenpol JA, Thiagalingan S, Gyruis J, Kinzler KW and Vogelstein B . (1993). Nature, 362, 857–860.

  • Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG and Lozano G . (2001). Nat. Genet., 29, 92–95.

  • Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ and Jochemsen AG . (2001). Cancer Res., 61, 1839–1842.

  • Samuels-Lev Y, O’Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X . (2001). Mol. Cell, 8, 781–794.

  • Slee EA, O’Connor DJ and Lu X . (2004). Oncogene, 23, 2809–2818.

  • Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK and Jochemsen AG . (2001). EMBO Rep., 2, 1029–1034.

  • Tang HJ, Qian D, Sondak VK, Stachura S and Lin J . (2004). Br. J. Cancer, 90, 1285–1292.

  • Vousden KH and Lu X . (2002). Nat. Rev. Cancer, 2, 594–604.

Download references

Acknowledgements

We thank Dr David Meek for Gal4-p53 fusion plasmid and Mr Alan Renton for reading this paper. This work is mainly supported by Ludwig Institute for Cancer Research and DB is funded by AICR.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergamaschi, D., Samuels, Y., Zhong, S. et al. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. Oncogene 24, 3836–3841 (2005). https://doi.org/10.1038/sj.onc.1208535

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208535

Keywords

This article is cited by

Search

Quick links